Real-world data backs tocilizumab for systemic JIA

Tocilizumab is an effective treatment that is well tolerated by patients with systemic juvenile idiopathic arthritis, real world data from Japan shows.

The study of 417 patients over 52 weeks found mean CRP levels decreasing from a baseline level of 2.7mg/dL to 0.5mg/dL four weeks after tocilizumab initiation.

CRP levels remained within normal range (defined as levels below 0.3mg/dL) from week 8 to week 52,